Circulation journal : official journal of the Japanese Circulation Society · 2005
Percutaneous transvenous mitral commissurotomy and radiofrequency catheter ablation in patients with mitral stenosis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyaji Kohei, Tada Hiroshi, Ito Sachiko, Naito Shigeto, Yamada Minoru, Hashimoto Tohru, Hoshizaki Hiroshi, Oshima Shigeru, Taniguchi Koichi
Аннотация
BACKGROUND: The purpose of this study was to evaluate the short- and long-term results of radiofrequency catheter ablation (RFCA) for the treatment of atrial fibrillation (AF) in patients with mitral stenosis (MS) following percutaneous transvenous mitral commissurotomy (PTMC).
METHODS AND RESULTS: Four patients (2 males, age 59+/-6 years) underwent simultaneous PTMC and pulmonary vein (PV) ablation. All patient had AF and MS (2 had persistent AF >1 month, 2 had paroxysmal AF), and the mean duration of AF was 3.4+/-3.3 years. The mean left atrial dimension was 47+/-7 mm and the mean ejection fraction was 58+/-4%. After PTMC, RFCA was performed in all patients (3 underwent PV isolation and 1 had PV focal ablation). The mitral valve area increased from 1.11 +/-0.19 to 1.90+/-0.20 cm(2) (p < 0.01). The frequency of AF episodes was dramatically reduced in the 2 patients with paroxysmal AF, and the 1 with persistent AF maintained sinus rhythm, but 1 patient with persistent AF developed recurrent AF. No complications or cardiac events occurred in any of the patients.
CONCLUSION: The combination of RFCA and PTMC was safe and feasible, and may be useful in patients with MS and AF.
METHODS AND RESULTS: Four patients (2 males, age 59+/-6 years) underwent simultaneous PTMC and pulmonary vein (PV) ablation. All patient had AF and MS (2 had persistent AF >1 month, 2 had paroxysmal AF), and the mean duration of AF was 3.4+/-3.3 years. The mean left atrial dimension was 47+/-7 mm and the mean ejection fraction was 58+/-4%. After PTMC, RFCA was performed in all patients (3 underwent PV isolation and 1 had PV focal ablation). The mitral valve area increased from 1.11 +/-0.19 to 1.90+/-0.20 cm(2) (p < 0.01). The frequency of AF episodes was dramatically reduced in the 2 patients with paroxysmal AF, and the 1 with persistent AF maintained sinus rhythm, but 1 patient with persistent AF developed recurrent AF. No complications or cardiac events occurred in any of the patients.
CONCLUSION: The combination of RFCA and PTMC was safe and feasible, and may be useful in patients with MS and AF.